DE60119945D1 - Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40 - Google Patents
Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40Info
- Publication number
- DE60119945D1 DE60119945D1 DE60119945T DE60119945T DE60119945D1 DE 60119945 D1 DE60119945 D1 DE 60119945D1 DE 60119945 T DE60119945 T DE 60119945T DE 60119945 T DE60119945 T DE 60119945T DE 60119945 D1 DE60119945 D1 DE 60119945D1
- Authority
- DE
- Germany
- Prior art keywords
- antigen
- cell
- antibody
- therapy
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 101150013553 CD40 gene Proteins 0.000 title 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 5
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 4
- 108010063916 CD40 Antigens Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 230000003211 malignant effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23755600P | 2000-10-02 | 2000-10-02 | |
US237556P | 2000-10-02 | ||
PCT/US2001/030963 WO2002028481A2 (en) | 2000-10-02 | 2001-10-02 | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60119945D1 true DE60119945D1 (de) | 2006-06-29 |
DE60119945T2 DE60119945T2 (de) | 2007-01-18 |
Family
ID=22894238
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60119945T Expired - Lifetime DE60119945T2 (de) | 2000-10-02 | 2001-10-02 | VERFAHREN ZUR THERAPIE VON B-ZELLMALIGNITÄTEN UNTER VERWENDUNG VON ANTAGONISTISCHEN ANTI-CD40-Antikörpern |
DE60143535T Expired - Lifetime DE60143535D1 (de) | 2000-10-02 | 2001-10-02 | Humane antikörper gegen cd40 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60143535T Expired - Lifetime DE60143535D1 (de) | 2000-10-02 | 2001-10-02 | Humane antikörper gegen cd40 |
Country Status (10)
Country | Link |
---|---|
US (5) | US7288252B2 (de) |
EP (3) | EP1717251B1 (de) |
JP (6) | JP4202127B2 (de) |
AT (3) | ATE489403T1 (de) |
AU (4) | AU2001296545A1 (de) |
CA (2) | CA2424749A1 (de) |
DE (2) | DE60119945T2 (de) |
ES (1) | ES2357051T3 (de) |
PT (1) | PT1326896E (de) |
WO (4) | WO2002028481A2 (de) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
ES2357051T3 (es) | 2000-10-02 | 2011-04-15 | Novartis Vaccines And Diagnostics, Inc. | Anticuerpos humanos anti-cd40. |
US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7507724B2 (en) * | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
CA2544368C (en) | 2003-11-04 | 2014-04-01 | Chiron Corporation | Methods of therapy for b cell-related cancers |
WO2005044855A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
CA2544852A1 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
PT1682178E (pt) * | 2003-11-04 | 2010-10-21 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros que expressam o antigénio cd40 |
PT1682177E (pt) * | 2003-11-04 | 2010-11-29 | Xoma Technology Lt | Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
WO2006109045A2 (en) | 2005-04-09 | 2006-10-19 | Fusion Antibodies Limited | Cathepsin s antibody |
US8337851B2 (en) * | 2005-05-18 | 2012-12-25 | Novartis Ag | Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer |
PL1889065T3 (pl) | 2005-05-18 | 2013-12-31 | Novartis Ag | Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny |
KR20080073725A (ko) * | 2005-11-01 | 2008-08-11 | 노파르티스 아게 | 항-cd40 항체의 용도 |
US20090053221A1 (en) * | 2006-01-17 | 2009-02-26 | Cheung Nai-Kong V | Immune response enhancing glucan |
US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
WO2007124299A2 (en) | 2006-04-21 | 2007-11-01 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
US7993648B2 (en) * | 2006-05-03 | 2011-08-09 | The Regents of the Universitry of Colorado | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
ES2659517T3 (es) | 2007-05-30 | 2018-03-16 | Xencor, Inc. | Métodos y composiciones para inhibir células que expresan CD32B |
RU2491095C2 (ru) * | 2007-11-09 | 2013-08-27 | Новартис Аг | Применения анти-cd40-антител |
US8551485B2 (en) | 2008-01-23 | 2013-10-08 | Xencor, Inc. | Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells |
WO2010104747A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted vaccines |
MX2011009438A (es) | 2009-03-10 | 2012-04-02 | Baylor Res Inst | Anticuerpos anti-cd40 y usos de los mismos. |
MX2011009439A (es) | 2009-03-10 | 2013-06-18 | Baylor Res Inst | Vacunas con especificidad de objetivo hacia celula presentadora de antigeno. |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
HUE044591T2 (hu) | 2011-03-11 | 2019-11-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásuk |
US20120301465A1 (en) | 2011-03-25 | 2012-11-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods to immunize against hepatitis c virus |
DK2699601T3 (en) | 2011-04-21 | 2018-04-23 | Bristol Myers Squibb Co | ANTIBODY POLYPEPTIDES ANTAGONIZING CD40 |
EP2780372B1 (de) * | 2011-11-17 | 2019-01-02 | Jung, Gundram | Bispezifische antikörper zur medizinischen verwendung |
JP2016011258A (ja) * | 2012-10-26 | 2016-01-21 | 株式会社ペルセウスプロテオミクス | 抗ヒトcd40モノクローナル抗体及びその利用 |
ES2649991T3 (es) | 2012-11-19 | 2018-01-16 | Baliopharm Ag | Anticuerpo biespecífico recombinante que se une a CD20 y CD95 |
US10286058B2 (en) | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
EP3113796A1 (de) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Verfahren zur verwendung von antikörperpolypeptiden mit cd40-antagonisierung zur behandlung von entzündlichen darmerkrankungen |
WO2016069919A1 (en) | 2014-10-29 | 2016-05-06 | Seattle Genetics, Inc. | Dosage and administration of non-fucosylated anti-cd40 antibodies |
KR102656470B1 (ko) | 2014-12-10 | 2024-04-09 | 리전츠 오브 더 유니버스티 오브 미네소타 | 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기 |
SI3303395T1 (sl) | 2015-05-29 | 2020-03-31 | Abbvie Inc. | Protitelesa proti CD40 in njihove uporabe |
SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
BR112018006360A2 (pt) | 2015-09-30 | 2018-10-09 | Janssen Biotech Inc | anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso |
EP4371570A3 (de) | 2016-06-08 | 2024-07-17 | Xencor, Inc. | Behandlung von erkrankungen im zusammenhang mit igg4 mit anti-cd19-antikörpern mit kreuzbindung an cd32b |
KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
CA3030636A1 (en) | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
MX2019014375A (es) | 2017-06-01 | 2020-01-23 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. |
CN108503708B (zh) * | 2017-09-01 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd47抗体及其用途 |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
AU2019287765A1 (en) | 2018-06-15 | 2021-01-07 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
US20210355216A1 (en) | 2018-10-05 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2020108611A1 (zh) | 2018-11-30 | 2020-06-04 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及其医药用途 |
CA3121291A1 (en) | 2018-11-30 | 2020-06-04 | Jiangsu Hengrui Medicine Co., Ltd. | Cd40 antibody pharmaceutical composition and use thereof |
NL2022494B1 (en) * | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
EP3917960A1 (de) * | 2019-02-01 | 2021-12-08 | LAVA Therapeutics N.V. | Neuartige cd40-bindende antikörper |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
KR20230157315A (ko) | 2021-01-28 | 2023-11-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법 |
CA3211334A1 (en) | 2021-03-09 | 2022-09-15 | Yali FU | Multispecific binding agents against cd40 and cd137 in therapy |
WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
EP4363059A1 (de) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Zur förderung der apo-übertragung manipulierte immunzellen und verwendungen davon |
IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
CN117500816A (zh) | 2021-08-26 | 2024-02-02 | 映恩生物制药(苏州)有限公司 | 一种甾体化合物及其缀合物 |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US142358A (en) * | 1873-09-02 | Improvement in the purification of illuminating-gas | ||
US59427A (en) * | 1866-11-06 | Improvement in fences | ||
US4355023A (en) * | 1980-09-30 | 1982-10-19 | The Massachusetts General Hospital | Antibody fragment compositions and process |
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
US4689299A (en) * | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
NZ212051A (en) * | 1984-05-18 | 1988-10-28 | Univ Australian | Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation |
US5068223A (en) * | 1985-09-09 | 1991-11-26 | Board Of Regents, University Of Texas System | Hydrophobic peptide esters and amides |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5182368A (en) * | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
US4923872A (en) * | 1986-08-26 | 1990-05-08 | Warner-Lambert Co. | Analogues of pyrrolo[3,2d]pyrimidin-4-ones |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
ATE68347T1 (de) * | 1987-01-17 | 1991-11-15 | Asta Pharma Ag | Synergistische kombination von azelastin und theophyllin oder azelastin und beta-mimetika. |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
EP0434879A1 (de) | 1989-12-14 | 1991-07-03 | Schering-Plough | Verfahren zur Herstellung von faktorabhÀ¤ngigen menschlichen B-Zellinien |
EP0537293A4 (en) | 1990-07-02 | 1993-09-08 | Bristol-Myers Company | Ligand for cd28 receptor on b cells and methods |
DE69233051T2 (de) | 1991-10-25 | 2004-03-11 | Immunex Corp., Seattle | Antikörper gegen CD40-L |
JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
CA2139571C (en) | 1992-07-07 | 2006-11-14 | Eleanor N. Fish | Interferon receptor binding peptides |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
ATE258595T1 (de) | 1992-07-09 | 2004-02-15 | Chiron Corp | Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle |
US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
WO1994004570A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
ATE255906T1 (de) | 1993-10-01 | 2003-12-15 | Immunex Corp | Antikörper gegen cd40 |
JPH09507074A (ja) * | 1993-12-23 | 1997-07-15 | イミュネックス・コーポレーション | Cd40を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法 |
AU2466895A (en) * | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
EP1221973B1 (de) * | 1999-10-04 | 2007-05-30 | Novartis Vaccines and Diagnostics, Inc. | CD40 Antagonist zur Behandlung von Psoriasis |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2001034649A2 (en) | 1999-11-09 | 2001-05-17 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
WO2001083755A2 (en) * | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
ES2357051T3 (es) * | 2000-10-02 | 2011-04-15 | Novartis Vaccines And Diagnostics, Inc. | Anticuerpos humanos anti-cd40. |
-
2001
- 2001-10-02 ES ES01979395T patent/ES2357051T3/es not_active Expired - Lifetime
- 2001-10-02 AU AU2001296545A patent/AU2001296545A1/en not_active Abandoned
- 2001-10-02 AT AT01979395T patent/ATE489403T1/de active
- 2001-10-02 EP EP06005656A patent/EP1717251B1/de not_active Expired - Lifetime
- 2001-10-02 AU AU2001296507A patent/AU2001296507A1/en not_active Abandoned
- 2001-10-02 DE DE60119945T patent/DE60119945T2/de not_active Expired - Lifetime
- 2001-10-02 JP JP2002532304A patent/JP4202127B2/ja not_active Expired - Fee Related
- 2001-10-02 WO PCT/US2001/030963 patent/WO2002028481A2/en active IP Right Grant
- 2001-10-02 PT PT01979395T patent/PT1326896E/pt unknown
- 2001-10-02 WO PCT/US2001/030857 patent/WO2002028904A2/en active Application Filing
- 2001-10-02 EP EP01979395A patent/EP1326896B1/de not_active Expired - Lifetime
- 2001-10-02 JP JP2002532486A patent/JP4271440B2/ja not_active Expired - Lifetime
- 2001-10-02 CA CA002424749A patent/CA2424749A1/en not_active Abandoned
- 2001-10-02 AU AU2001296547A patent/AU2001296547A1/en not_active Abandoned
- 2001-10-02 US US10/380,223 patent/US7288252B2/en not_active Expired - Fee Related
- 2001-10-02 AT AT06005656T patent/ATE541860T1/de active
- 2001-10-02 AT AT01977428T patent/ATE327004T1/de not_active IP Right Cessation
- 2001-10-02 AU AU2002211366A patent/AU2002211366A1/en not_active Abandoned
- 2001-10-02 CA CA002424296A patent/CA2424296A1/en not_active Abandoned
- 2001-10-02 WO PCT/US2001/030859 patent/WO2002028905A2/en active Application Filing
- 2001-10-02 WO PCT/US2001/030961 patent/WO2002028480A2/en active Application Filing
- 2001-10-02 EP EP01977428A patent/EP1322383B9/de not_active Expired - Lifetime
- 2001-10-02 DE DE60143535T patent/DE60143535D1/de not_active Expired - Lifetime
-
2007
- 2007-08-31 US US11/849,107 patent/US7445780B2/en not_active Expired - Fee Related
- 2007-11-19 JP JP2007299859A patent/JP2008156339A/ja active Pending
- 2007-11-26 JP JP2007305086A patent/JP2008074870A/ja active Pending
-
2008
- 2008-08-28 JP JP2008220544A patent/JP4838831B2/ja not_active Expired - Fee Related
- 2008-10-06 US US12/246,029 patent/US7611708B2/en not_active Expired - Fee Related
-
2009
- 2009-06-16 JP JP2009143746A patent/JP2009201523A/ja active Pending
- 2009-09-28 US US12/568,373 patent/US7820170B2/en not_active Expired - Fee Related
-
2010
- 2010-09-27 US US12/891,415 patent/US8088383B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60119945D1 (de) | Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40 | |
SG148143A1 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
CY1111011T1 (el) | Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος | |
WO2005044304A3 (en) | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia | |
DE69709632T2 (de) | Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung | |
CY1110874T1 (el) | Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας | |
DK2371391T3 (da) | Terapeutisk anvendelse af anti-CS1-antistoffer | |
DK1684869T3 (da) | Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme | |
DE69414398T2 (de) | Heterocyclische neurokinin-antagonisten | |
IS6105A (is) | Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4 | |
ATE488250T1 (de) | Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma | |
TR200103432T2 (tr) | Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı. | |
BR0315140A (pt) | Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação | |
WO2004019991A3 (en) | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma | |
CY1114654T1 (el) | Anti-cd40 μονοκλωνικα αντισωματα ανταγωνιστες και μεθοδοι για την χρηση αυτων | |
NZ329403A (en) | Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US |